Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021

Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021

<b>Background:</b> Palbociclib, when combined with endocrine therapy, represents a valuable treatment option for patients diagnosed with hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer (BC) or metastatic breast cancer (MBC)....

Full description

Saved in:

Bibliographic Details
Main Authors:	Cristina Marinela Oprean, Larisa Maria Badau, Ramona Petrita, Mircea Dragos Median, Alis Dema
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Diagnostics
Subjects:	breast cancer cyclin-dependent kinase 4/6 inhibitor palbociclib real-world Her2 low Ki67
Online Access:	https://www.mdpi.com/2075-4418/15/9/1173
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer
by: Xiangjun Li, et al.
Published: (2025-07-01)

Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review
by: Aryan Salahi‐Niri, et al.
Published: (2025-03-01)

Immunohistochemical Expression of Cyclin D1 in Invasive Breast Carcinoma
by: Tabish Hassan, et al.
Published: (2024-10-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial
by: Samar A. Dewidar, et al.
Published: (2022-10-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01)

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)
by: Jieun Lee, et al.
Published: (2025-08-01)

Neoplasias astrocitárias e correlação com as proteínas p53 mutada e Ki-67 Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins
by: Gustavo Rassier Isolan, et al.
Published: (2005-12-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01)

Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers
by: Nastaran Zerang, et al.
Published: (2025-05-01)

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma
by: Vishwanath Kurawattimath, et al.
Published: (2025-08-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

CDX2 expression in gastric carcinoma: A clinicopathological study
by: Aniket Halder, et al.
Published: (2018-01-01)

Cisplatin palbociclib combination differentially modulates PTEN AKT signaling via Hsp90 in hepatocellular carcinoma cells
by: Hameis M. Sleem, et al.
Published: (2025-06-01)

Phosphohistone H3 as the standard of immunohistochemical study in the assessment of differentiation level of oropharyngeal zone squamous cell carcinomas
by: А. V. Lysak, et al.
Published: (2016-08-01)

Cyclooxygenase-2 and Ki67 Expression in Oral Leukoplakia: a Clinicopathological Study
by: Alper Sinanoglu, et al.
Published: (2015-06-01)

BIOLOGICAL MARKERS OF THE Ki-67 CELL CYCLE AND Bcl-2 IN MYOMA, ADENOMYOSIS, AND LEIOMYOSARCOMA UTERI
by: Светлана Владимировна Шрамко, et al.
Published: (2019-09-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

Significance and limitations of routine p16/Ki-67 immunohistochemistry as a diagnostic tool for high-grade squamous intraepithelial lesions of the uterine cervix
by: Kazutaka Ozono, et al.
Published: (2025-01-01)

Role of diffuse endocrine system and cellular homeostasis of epithelial cells of the stomach mucosa in development and progression of peptic ulcer of the duodenum
Published: (2009-08-01)

MRI-based multiregional radiomics for preoperative prediction of Ki-67 expression in meningiomas: a two-center study
by: Ming Luo, et al.
Published: (2025-07-01)

A deep learning model to predict Ki-67 positivity in oral squamous cell carcinoma
by: Francesco Martino, et al.
Published: (2024-12-01)

Association between histologic grades and Ki67 score in breast cancer
by: Dr Shumaila Nawaz Khan Khan, et al.
Published: (2025-03-01)

Assessment of the Relationship between Ki-67 Expression and Different Clinicopathological Factors of Adenoid Cystic Carcinoma: A Retrospective Immunohistochemical Study
by: Mohammed Al Zubidi, et al.
Published: (2025-03-01)

CD4+ lymphocytopenia and Pneumocystis jirovecii pneumonia in a metastatic breast cancer patient treated with palbociclib and corticosteroids
by: Shahar Dekel, et al.
Published: (2025-07-01)

Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens Prolactinoma metastático: relato de caso com avaliação imuno-histoquímica para os antígenos p53 e Ki-67
by: Paulo S. Crusius, et al.
Published: (2005-09-01)

Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
by: Shun-Hua Chen, et al.
Published: (2025-06-01)

Clinical Prognosis and Nomograms for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy
by: Song S, et al.
Published: (2025-07-01)

Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
by: Saiqa Nisar, et al.
Published: (2024-10-01)

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
by: Rachel M. Layman, et al.
Published: (2025-06-01)

Antibodies and anti-antibodies specific to estradiol and progesterone and tumor proliferation in breast cancer patients
by: A. N. Glushkov, et al.
Published: (2024-07-01)

Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas
by: Zilan Luo, et al.
Published: (2025-12-01)

Mitotic activity and nucleic acids content in the cells’ nuclei of epithelial colon tumors
by: A.N. Grabovoy, et al.
Published: (2013-08-01)

A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group
by: Subhalakshmi Sengupta, et al.
Published: (2012-01-01)

The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand
by: Phanchaporn Wongmaneerung, et al.
Published: (2025-02-01)

Prognostic Importance of Ki-67 Expression in Early-Stage Glottic Larynx Cancer Treated with Radiotherapy
by: Gül Kanyılmaz, et al.
Published: (2023-10-01)